Silvia Castelletti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2247539/publications.pdf

Version: 2024-02-01

75 papers	2,397 citations	218677 26 h-index	214800 47 g-index
77 all docs	77 docs citations	77 times ranked	3613 citing authors

#	Article	IF	Citations
1	Clinical application of CMR in cardiomyopathies: evolving concepts and techniques. Heart Failure Reviews, 2023, 28, 77-95.	3.9	19
2	Hypertrophic cardiomyopathy: insights from extracellular volume mapping. European Journal of Preventive Cardiology, 2022, 28, e39-e41.	1.8	6
3	Cardiology in 280 characters. European Heart Journal, 2022, 43, 1186-1188.	2.2	1
4	Fear of Sudden Death During Sport Activity and the Long QT Syndrome. , 2022, , 127-137.		0
5	Left Cardiac Sympathetic Denervation for Long QT Syndrome. JACC: Clinical Electrophysiology, 2022, 8, 281-294.	3.2	25
6	Effective Study: Development and Application of a Questionâ€Driven, Timeâ€Effective Cardiac Magnetic Resonance Scanning Protocol. Journal of the American Heart Association, 2022, 11, e022605.	3.7	1
7	Gender Differences in International Cardiology Guideline Authorship: A Comparison of the US, Canadian, and European Cardiology Guidelines From 2006 to 2020. Journal of the American Heart Association, 2022, 11, e024249.	3.7	16
8	Diagnosis and Management of Rare Cardiomyopathies in Adult and Paediatric Patients. A Position Paper of the Italian Society of Cardiology (SIC) and Italian Society of Paediatric Cardiology (SICP). International Journal of Cardiology, 2022, 357, 55-71.	1.7	36
9	Sports cardiology in Europe from the ancient Greek-Roman era to the present. European Heart Journal, 2022, 43, 2542-2544.	2.2	4
10	The athleteâ€™s heart from Philippides to the modern marathon runners. European Heart Journal, 2022, 43, 2538-2541.	2.2	1
11	Molecular genetic testing in athletes: Why and when a position statement from the Italian Society of Sports Cardiology. International Journal of Cardiology, 2022, 364, 169-177.	1.7	6
12	Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part 2: ventricular arrhythmias, channelopathies, and implantable defibrillators. Europace, 2021, 23, 147-148.	1.7	47
13	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. Genetics in Medicine, 2021, 23, 47-58.	2.4	57
14	Appropriate use criteria for cardiovascular magnetic resonance imaging (CMR): SICâ€”SIRM position paper part 1 (ischemic and congenital heart diseases, cardio-oncology, cardiac masses and heart) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2	1.7	26
15	Appropriate use criteria for cardiovascular MRI: SIC â€“ SIRM position paper Part 2 (myocarditis,) Tj ETQq1 1 0.784314 rgBT /Overlock 1 2021, 22, 515-529.	1.5	9
16	Age-dependent diagnostic yield of echocardiography as a second-line diagnostic investigation in athletes with abnormalities at preparticipation screening. Journal of Cardiovascular Medicine, 2021, 22, 759-766.	1.5	2
17	COVID-19 and Cardiovascular Disease: a Global Perspective. Current Cardiology Reports, 2021, 23, 135.	2.9	27
18	Mutation location and I ÂKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region. European Heart Journal, 2021, 42, 4743-4755.	2.2	26

#	Article	IF	Citations
19	Remote Monitoring of the QT Interval and Emerging Indications for Arrhythmia Prevention. Cardiac Electrophysiology Clinics, 2021, 13, 523-530.	1.7	7
20	Mitral valve prolapse and sport: how much prolapse is too prolapsing?. European Journal of Preventive Cardiology, 2021, 28, 1100-1101.	1.8	0
21	The Female Athleteâ€™s Heart: Overview and Management of Cardiovascular Diseases. European Cardiology Review, 2021, 16, e47.	2.2	9
22	Partial Pericardial Agenesis Mimicking Arrhythmogenic Right Ventricular Cardiomyopathy. Clinical Journal of Sport Medicine, 2020, 30, e159-e162.	1.8	3
23	To be, or not to be engaged in sport activities, that is the amletic question for patients with coronary artery disease. European Journal of Preventive Cardiology, 2020, 27, 767-769.	1.8	0
24	Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. International Journal of Cardiology, 2020, 300, 191-195.	1.7	60
25	Exercise Training-Induced Repolarization Abnormalities Masquerading as Congenital Long QT Syndrome. Circulation, 2020, 142, 2405-2415.	1.6	36
26	Promoting Prevention: A Call for Action. European Heart Journal, 2020, 41, 3292-3294.	2.2	0
27	SCN5A Mutation Type and a Genetic Risk Score Associate Variably With Brugada Syndrome Phenotype in SCN5A Families. Circulation Genomic and Precision Medicine, 2020, 13, e002911.	3.6	41
28	The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 394-404.	3.0	16
29	Abnormal myocardial expression of SAP97 is associated with arrhythmogenic risk. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H1357-H1370.	3.2	13
30	Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease. Circulation: Cardiovascular Imaging, 2020, 13, e010171.	2.6	35
31	A Shift on the Front Line. New England Journal of Medicine, 2020, 382, e83.	27.0	13
32	Specific Cardiovascular Diseases and Competitive Sports Participation: Channelopathies. , 2020, , 361-402.		0
33	Management of nonischemic-dilated cardiomyopathies in clinical practice: a position paper of the working group on myocardial and pericardial diseases of Italian Society of Cardiology. Journal of Cardiovascular Medicine, 2020, 21, 927-943.	1.5	5
34	European Journal of Preventive Cardiology. European Heart Journal, 2019, 40, 2478-2478.	2.2	0
35	The Membership Committee of the ESC. Cardiovascular Research, 2019, 115, e130-e132.	3.8	0
36	Heart failure in patients with arrhythmogenic right ventricular cardiomyopathy: Genetic characteristics. International Journal of Cardiology, 2019, 286, 99-103.	1.7	10

#	Article	IF	Citations
37	Dietary components and risk of cardiovascular disease and all-cause mortality: A review under the sign of the carrot. European Journal of Preventive Cardiology, 2019, 26, 1412-1414.	1.8	4
38	From the last EuroPrevent towards the first ESC Preventive Cardiology Congress. European Journal of Preventive Cardiology, 2019, 26, 1408-1411.	1.8	0
39	Mexiletine Shortens the QT Interval in Patients With Potassium Channelâ€“Mediated Type 2 Long QT Syndrome. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007280.	4.8	74
40	Risk score for the exclusion of arrhythmic events in arrhythmogenic right ventricular cardiomyopathy at first presentation. International Journal of Cardiology, 2019, 290, 100-105.	1.7	8
41	From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2. European Heart Journal, 2019, 40, 1832-1836.	2.2	69
42	Ablation compared with drug therapy for recurrent ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy: Results from a multicenter study. Heart Rhythm, 2019, 16, 536-543.	0.7	35
43	Texture analysis of cardiovascular magnetic resonance cine images differentiates aetiologies of left ventricular hypertrophy. Clinical Radiology, 2019, 74, 140-149.	1.1	39
44	Lossâ€ofâ€function desmoplakin I and II mutations underlie dominant arrhythmogenic cardiomyopathy with a hair and skin phenotype. British Journal of Dermatology, 2019, 180, 1114-1122.	1.5	41
45	The Young Community of the European Association of Preventive Cardiology: The future in motion. European Journal of Preventive Cardiology, 2018, 25, 567-568.	1.8	3
46	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi003-A from a patient affected by an autosomal recessive form of Long QT Syndrome type 1. Stem Cell Research, 2018, 29, 170-173.	0.7	6
47	The genetics underlying idiopathic ventricular fibrillation: A special role for catecholaminergic polymorphic ventricular tachycardia?. International Journal of Cardiology, 2018, 250, 139-145.	1.7	42
48	Advanced Arrhythmogenic Cardiomyopathy in Former Marathon Runner. Circulation: Cardiovascular Imaging, 2018, 11, e008204.	2.6	0
49	Long and Short QT Syndromes. Cardiac and Vascular Biology, 2018, , 147-185.	0.2	0
50	EuroPrevent 2018, cardiovascular prevention at its highest levels. European Journal of Preventive Cardiology, 2018, 25, 1127-1130.	1.8	0
51	A wearable remote monitoring system for the identification of subjects with a prolonged QT interval or at risk for drug-induced long QT syndrome. International Journal of Cardiology, 2018, 266, 89-94.	1.7	53
52	Diagnostic clues for the diagnosis of nonsarcomeric hypertrophic cardiomyopathy (Phenocopies): Amyloidosis, fabry disease, and mitochondrial disease. Journal of Cardiovascular Echography, 2018, 28, 120.	0.4	10
53	Electrocardiographic differentiation of idiopathic right ventricular outflow tract ectopy from early arrhythmogenic right ventricular cardiomyopathy. Europace, 2017, 19, euw018.	1.7	20
54	Desmoplakin missense and non-missense mutations in arrhythmogenic right ventricular cardiomyopathy: Genotype-phenotype correlation. International Journal of Cardiology, 2017, 249, 268-273.	1.7	70

#	Article	IF	Citations
55	Clinical recommendations of cardiac magnetic resonance, Part I. Journal of Cardiovascular Medicine, 2017, 18, 197-208.	1.5	26
56	Late gadolinium enhancement in Brugada syndrome: A marker for subtle underlying cardiomyopathy?. Heart Rhythm, 2017, 14, 583-589.	0.7	38
57	Clinical recommendations of cardiac magnetic resonance, Part II. Journal of Cardiovascular Medicine, 2017, 18, 209-222.	1.5	22
58	Evolution in Managing Long QT Syndrome. Journal of the American College of Cardiology, 2017, 70, 463-465.	2.8	1
59	Reference values of cardiac volumes, dimensions, and new functional parameters by MR: A multicenter, multivendor study. Journal of Magnetic Resonance Imaging, 2017, 45, 1055-1067.	3.4	82
60	Insight into hypertrophied hearts: a cardiovascular magnetic resonance study of papillary muscle mass and T1 mapping. European Heart Journal Cardiovascular Imaging, 2017, 18, 1034-1040.	1.2	31
61	Left Ventricular Hypertrophy Revisited. Circulation, 2017, 136, 2519-2521.	1.6	37
62	Arrhythmogenic right ventricular cardiomyopathy in Boxer dogs: the diagnosis as a link to the human disease. Acta Myologica, 2017, 36, 135-150.	1.5	8
63	Cardiovascular magnetic resonance in hypertrophic cardiomyopathy and infiltrative cardiomyopathy. South African Journal of Radiology, 2016, 20, .	0.3	0
64	Cardiac Fabry Disease With Late Gadolinium Enhancement Is a Chronic Inflammatory Cardiomyopathy. Journal of the American College of Cardiology, 2016, 68, 1707-1708.	2.8	78
65	Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	210
66	The ventricular ectopic QRS interval (VEQSI): Diagnosis of arrhythmogenic right ventricular cardiomyopathy in patients with incomplete disease expression. Heart Rhythm, 2016, 13, 1504-1512.	0.7	13
67	Automatic Measurement of the MyocardialÂInterstitium. JACC: Cardiovascular Imaging, 2016, 9, 54-63.	5.3	127
68	Epicardial myocardial strain abnormalities may identify the earliest stages of arrhythmogenic cardiomyopathy. International Journal of Cardiovascular Imaging, 2016, 32, 593-601.	1.5	18
69	Myocardial T1 Mapping. Circulation Journal, 2015, 79, 487-494.	1.6	69
70	Abnormal septal convexity into the left ventricle occurs in subclinical hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 64.	3.3	19
71	Diagnosis and management of hypertrophic cardiomyopathy. Journal of Animal Science and Technology, 2015, 2, R45-R53.	2.5	21
72	A comprehensive electrocardiographic, molecular, and echocardiographic study of Brugada syndrome: Validation of the 2013 diagnostic criteria. Heart Rhythm, 2014, 11, 1176-1183.	0.7	32

#	Article	IF	Citations
73	Native T1 Mapping in Transthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2014, 7, 157-165.	5.3	339
74	Native T1 mapping in ATTR cardiac amyloidosis - comparison with AL cardiac amyloidosis - a 200 patient study. Journal of Cardiovascular Magnetic Resonance, 2014, 16, O4.	3.3	2
75	Spectrum and Prevalence of Mutations Involving BrS1- Through BrS12-Susceptibility Genes in a Cohort of Unrelated Patients Referred for Brugada Syndrome Genetic Testing. Journal of the American College of Cardiology, 2012, 60, 1410-1418.	2.8	193